DeciBio
Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment
Premium
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.
NIPT, Oncology to Drive NGS MDx Market Growth by 2015; Most Tests to Remain Targeted, Lab-Developed
Premium
The market for next-generation sequencing-based molecular diagnostic tests is poised to grow more than tenfold between 2012 and 2015, driven by non-invasive prenatal and oncology tests, most of them targeted, according to a recent report from research firm DeciBio.
Next-generation sequencing is helping to drive the emerging market in single-cell genomics, according to a report by Culver City, Calif.-based market research firm DeciBio.
Report Says Desktops Will Drive 20 Percent Annual NGS Growth; Illumina, Life Tech to Remain Dominant
Premium
The next-generation sequencing market is poised to grow 20 percent per year from around $1.2 billion currently to $2.1 billion by 2015, driven in large part by desktop sequencers, according to a recent report by Los Angeles-based market research firm DeciBio.
Report Sees Continued Growth for Fluidigm as Company Remains 'Interesting' Acquisition Target
Premium
Fluidigm's product revenues are expected to grow 27 percent annually over the next four years, buoyed by the company's participation in three rapidly growing niche markets — sample preparation for next-gen sequencing, single-cell genomics, and digital PCR — according to a market
Feb 16, 2012